No Trial? No Problem. FDA Rewrites the RNA Rules

FDA's Plausible Mechanism Framework opens a structured US approval route for RNA-based therapies targeting ultra-rare genetic diseases

26 Mar 2026

The US Food and Drug Administration has outlined a new regulatory pathway for RNA-based and gene-editing therapies aimed at ultra-rare genetic diseases, conditions where conventional clinical trials are often impractical given the small number of patients affected.

The Plausible Mechanism Framework, published in draft form on 23 February 2026, would allow developers to seek approval on the basis of biological rationale and targeted clinical evidence rather than the large randomised controlled trials that have historically been required. For diseases affecting only a handful of patients nationwide, the shift represents a significant change in how the agency evaluates therapeutic evidence.

Under the proposed criteria, a therapy must target the specific genetic or molecular root cause of a disease, demonstrate effective engagement with that target in patients, and draw on documented natural history data from untreated patients as a clinical reference point. The FDA also indicated that gene-editing therapies addressing multiple mutations within a single gene could be grouped under master protocols, reducing the cost and time of running separate studies for each variant.

The guidance was developed jointly by the Centre for Biologics Evaluation and Research and the Centre for Drug Evaluation and Research. The agency signalled that the framework could extend beyond RNA therapies to broader personalised medicine programmes where conventional trial design is not feasible.

The draft follows a November 2025 article in the New England Journal of Medicine co-authored by FDA Commissioner Marty Makary and CBER Director Vinay Prasad. A public comment period runs until 27 April 2026, giving industry groups, patient organisations, and clinicians an opportunity to shape the final framework before it is adopted.

How broadly the framework will be applied in practice, and whether it will accelerate approvals at the pace advocates are hoping for, remains to be seen.